The therapeutic approach to advanced prostate cancer has seen greater changes in the last 7 years than it did in the preceding 70. Although only one of the newly approved agents that improve overall survival is a targeted agent, it is a validation of the method of pathway analysis and drug design in delivering novel, clinically usable agents. As our knowledge of the molecular circuitry of tumour invasion, metastases and treatment resistance has become more refined, the number of new, potentially useful, targets has grown exponentially. This is reflected in the vast array of diverse targeted agents that are currently being evaluated in human trials. In this review, we briefly describe some of the key pathways that are involved in the evolution of the prostate cancer 'lethal phenotype', and review the clinical activity of some of the newly approved targeted therapies or those in advanced phases of clinical development.
Written by:
Corcoran NM, Gleave ME. Are you the author?
Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville Australian Prostate Cancer Research Centre at Epworth, Richmond, Victoria, Australia; Department of Urological Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
Reference: Histopathology. 2012 Jan;60(1):216-31.
doi: 10.1111/j.1365-2559.2011.04030.x
PubMed Abstract
PMID: 22212088
UroToday.com Prostate Cancer Section
